Anonymity, the Production of Goods, and Institutional Design

Fordham Law Review, Forthcoming
Jeffrey Skopek

Abstract: In this article, I demonstrate that anonymity has been misconceived as an aspect of privacy, and that understanding this mistake reveals a powerful and underutilized set of legal tools for facilitating and controlling the production of information and other social…

Read More

Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing

Boston College Law Review, forthcoming
W. Nicholson Price II

Abstract:   Drug recalls, contamination events, and shortages are on the rise, but drug companies still rely on decades-old manufacturing plants and processes. Contrary to widespread perceptions, drug manufacturing is typically expensive, inefficient, and non-innovative.…

Read More

When Truth Cannot Be Presumed: The Regulation of Drug Promotion under an Expanding First Amendment

Boston University Law Review, 2014
Christopher T. Robertson

Abstract:       The Food, Drug, and Cosmetic Act (“FDCA”) requires that, prior to marketing a drug, the manufacturer must prove that it is safe and effective for the manufacturer’s intended uses, as shown on the proposed label.…

Read More

The Globalization of Health Care: Legal and Ethical Issues

Oxford University Press, 2013
I. Glenn Cohen, ed. (Faculty Director)

The Globalization of Health Care: Legal and Ethical Issues, edited by I.…

Read More

Do Damages Caps Reduce Medical Malpractice Insurance Premiums?: A Systematic Review of Estimates and the Methods Used to Produce Them

Research Handbook on the Economics of Torts, Edward Elgar Publishers, November 21, 2012
Kathryn Zeiler (Academic Fellow Alumna) & Lorian Hardcastle

Abstract:       Despite common claims made in policy debates, the theoretical connection between tort reform and medical malpractice insurance premiums is ambiguous. Simple models suggest reforms such as statutory damages caps reduce premiums. More elaborate models…

Read More